B. T. Hyman, C. H. Phelps, T. G. Beach, E. H. Bigio, N. J. Cairns et al., National Institute on AgingAlzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association, vol.8, p.3266529, 2012.

R. A. Sperling, P. S. Aisen, L. A. Beckett, D. A. Bennett, S. Craft et al., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, vol.7, p.3220946, 2011.

C. R. Jack, D. S. Knopman, S. D. Weigand, H. J. Wiste, P. Vemuri et al., An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease, Annals of neurology, vol.71, issue.6, p.22488240, 2012.

P. Central and P. , , p.3586223

C. R. Jack, D. S. Knopman, G. Chetelat, D. Dickson, A. M. Fagan et al., Suspected non-Alzheimer disease pathophysiology-concept and controversy, Nature reviews Neurology, vol.12, issue.2, p.4784257, 2016.

A. Caroli, A. Prestia, S. Galluzzi, C. Ferrari, W. M. Van-der-flier et al., Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression, Neurology, vol.84, issue.5, p.25568301, 2015.

P. Central and P. , , p.4336071

A. Prestia, A. Caroli, W. M. Van-der-flier, R. Ossenkoppele, B. Van-berckel et al., Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease, Neurology, vol.80, issue.11, p.23390179, 2013.

S. J. Vos, F. Verhey, L. Frolich, J. Kornhuber, J. Wiltfang et al., Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage, Brain: a journal of neurology, vol.138, p.5013930, 2015.

J. K. Chung, E. Plitman, S. Nakajima, F. Caravaggio, S. Shinagawa et al., The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimer's Pathology: A Brief Report, Journal of Alzheimer's disease: JAD, vol.60, issue.2, p.28826178, 2017.

C. R. Jack, D. A. Bennett, K. Blennow, M. C. Carrillo, H. H. Feldman et al., A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers, Neurology, vol.87, issue.5, p.4970664, 2016.

S. C. Burnham, P. Bourgeat, V. Dore, G. Savage, B. Brown et al., Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study, Lancet Neurol, vol.15, issue.10, p.27450471, 2016.

B. A. Gordon, T. Blazey, Y. Su, A. M. Fagan, D. M. Holtzman et al., Longitudinal beta-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology, JAMA neurology, vol.73, issue.10, p.5237381, 2016.

E. C. Mormino, K. V. Papp, D. M. Rentz, A. P. Schultz, M. Lapoint et al., Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals, JAMA neurology, vol.73, issue.10, p.5266522, 2016.

M. J. De-leon, E. Pirraglia, R. S. Osorio, L. Glodzik, L. Saint-louis et al., The nonlinear relationship between cerebrospinal fluid Abeta42 and tau in preclinical Alzheimer's disease, PloS one, vol.13, issue.2, p.5802432, 2018.

F. Mouton-liger, D. Wallon, A. C. Troussiere, R. Yatimi, J. Dumurgier et al., Impact of cerebrospinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study, Journal of neurology, vol.261, issue.1, p.24162039, 2014.

A. C. Troussiere, D. Wallon, F. Mouton-liger, R. Yatimi, P. Robert et al., Who needs cerebrospinal biomarkers? A national survey in clinical practice, Journal of Alzheimer's disease: JAD, vol.40, issue.4, p.24577469, 2014.

C. Paquet, E. Bouaziz-amar, E. Cognat, L. Volpe-gillot, V. Haddad et al., Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored for Cognitive Disorders, p.29966201, 2018.

A. Boumenir, E. Cognat, S. Sabia, C. Hourregue, M. Lilamand et al., CSF level of ?-amyloid peptide predicts mortality in Alzheimer's disease, vol.11, p.30922415, 2019.

N. Mattsson, U. Andreasson, S. Persson, M. C. Carrillo, S. Collins et al., CSF biomarker variability in the Alzheimer's Association quality control program, vol.9, p.3707386, 2013.

C. R. Jack, D. A. Bennett, K. Blennow, M. C. Carrillo, B. Dunn et al., Alzheimer's & dementia: the journal of the Alzheimer's Association, vol.14, p.5958625, 2018.

J. Dumurgier, O. Vercruysse, C. Paquet, S. Bombois, C. Chaulet et al., Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting, vol.9, p.23141384, 2013.

K. Yamaoka, T. Nakagawa, and T. Uno, Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations, Journal of pharmacokinetics and biopharmaceutics, vol.6, issue.2, pp.165-75, 1978.

J. M. Tarasoff-conway, R. O. Carare, R. S. Osorio, L. Glodzik, T. Butler et al., Clearance systems in the brain-implications for Alzheimer disease, Nature reviews Neurology, vol.11, issue.8, p.4694579, 2015.

R. J. Bateman, C. Xiong, T. L. Benzinger, A. M. Fagan, A. Goate et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. The New England journal of medicine, vol.367, p.3474597, 2012.

A. M. Fagan, C. Xiong, M. S. Jasielec, R. J. Bateman, A. M. Goate et al., Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease, Science translational medicine, vol.6, issue.226, p.24598588, 2014.

P. Central and P. , , p.4038930

L. F. Maia, S. A. Kaeser, J. Reichwald, M. Lambert, U. Obermuller et al., Increased CSF Abeta during the very early phase of cerebral Abeta deposition in mouse models, EMBO molecular medicine, vol.7, issue.7, p.25978969, 2015.

P. Central and P. , , p.4520655

J. F. Crary, J. Q. Trojanowski, J. A. Schneider, J. F. Abisambra, E. L. Abner et al., Primary agerelated tauopathy (PART): a common pathology associated with human aging, Acta neuropathologica, vol.128, issue.6, pp.755-66, 2014.

P. Central and P. , , p.4257842

K. A. Jellinger, I. Alafuzoff, J. Attems, T. G. Beach, N. J. Cairns et al., PART, a distinct tauopathy, different from classical sporadic Alzheimer disease, Acta neuropathologica, vol.129, issue.5, p.4534004, 2015.

C. Duyckaerts, H. Braak, J. P. Brion, L. Buee, D. Tredici et al., PART is part of Alzheimer disease, Acta neuropathologica, vol.129, issue.5, p.4405349, 2015.

C. Bouras, P. R. Hof, P. Giannakopoulos, J. P. Michel, and J. H. Morrison, Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a oneyear autopsy population from a geriatric hospital, Cerebral cortex, vol.4, issue.2, pp.138-50, 1991.

B. T. Hyman and T. Gomez-isla, The natural history of Alzheimer neurofibrillary tangles and amyloid deposits, Neurobiology of aging, vol.18, issue.4, p.9330968, 1997.

S. Tsartsalis, A. Xekardaki, P. R. Hof, E. Kovari, C. Bouras et al., Alzheimer-type lesions in cognitively normal subjects, Neurobiology of aging, vol.62, p.5743763, 2018.